A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC)

被引：0
|
作者：
Griffith, David [1 ]
Flume, Patrick [2 ]
Winthrop, Kevin [3 ]
Thomson, Rachel [4 ]
Wagner, Dirk [5 ,6 ]
Van Ingen, Jakko [7 ]
Micioni, Liza [8 ]
McGinnis, John P., II [8 ]
Fernandez, Carlos [8 ]
Eagle, Gina [8 ]
机构：
[1] Univ Texas Hlth Sci Ctr Tyler, Dept Med, Tyler, TX 75799 USA
[2] Med Univ South Carolina, Div Pulm Crit Care & Sleep Med, Charleston, SC 29425 USA
[3] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA
[4] Greenslopes Private Hosp, Gallipoli Med Res Ctr, Thorac Med, Brisbane, Qld, Australia
[5] Univ Med Ctr, Ctr Infect Dis & Travel Med, Freiburg, Germany
[6] Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany
[7] Radboud Univ Nijmegen, Dept Med Microbiol, Med Ctr, Nijmegen, Netherlands
[8] Insmed Inc, Clin, Bridgewater, NJ USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2015年 / 46卷
关键词：
Bacteria; Infections; Treatments;
D O I：
10.1183/13993003.congress-2015.PA3945
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA3945
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy–controlled, phase 2 multicenter study (ONE-BRIDGE)
    Kazuya Ichikado
    Toru Kotani
    Yasuhiro Kondoh
    Hideaki Imanaka
    Takeshi Johkoh
    Kiminori Fujimoto
    Shin Nunomiya
    Tomotaka Kawayama
    Masanori Sawada
    Eric Jenkins
    Sadatomo Tasaka
    Satoru Hashimoto
    [J]. Stem Cell Research & Therapy, 14
  • [42] An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First -Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
    Novell, Silvia
    Scagliotti, Giorgio
    de Castro, Gilberto, Jr.
    Kiyik, Murat
    Kowalyszyn, Ruben
    Deppermann, Karl-Matthias
    Arriola, Edurne
    Bosquee, Lionel
    Novosiadly, Ruslan D.
    Nguyen, Tuan S.
    Forest, Amelie
    Tang, Shande
    Kambhampati, Siva Rama Prasad
    Cosaert, Jan
    Reck, Martin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 383 - 389
  • [43] Local analgesic effect of a bioadhesive barrier-forming oral liquid in cancer patients with oral mucositis caused by chemotherapy and/or radiotherapy: a randomized multicenter, single-use, positive-controlled, open-label study
    Cheng, Yuan
    Qin, Shu Kui
    Chen, Yan Ping
    Dong, Li Hua
    Sun, Xiang Dong
    Yu, Shi Ying
    Wu, Shi Kai
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 8555 - 8564
  • [44] Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy-controlled, phase 2 multicenter study (ONE-BRIDGE)
    Ichikado, Kazuya
    Kotani, Toru
    Kondoh, Yasuhiro
    Imanaka, Hideaki
    Johkoh, Takeshi
    Fujimoto, Kiminori
    Nunomiya, Shin
    Kawayama, Tomotaka
    Sawada, Masanori
    Jenkins, Eric
    Tasaka, Sadatomo
    Hashimoto, Satoru
    [J]. STEM CELL RESEARCH & THERAPY, 2023, 14 (01)
  • [45] Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors
    Kulasekararaj, Austin
    He, Guangsheng
    Munir, Talha
    Pu, Jeffrey
    Risitano, Antonio
    Roth, Alexander
    Sima, Camelia S.
    Appius, Anita
    Sostelly, Alexandre
    Sreckovic, Sasha
    Vignal, Charlotte
    Nishimura, Jun-Ichi
    [J]. BLOOD, 2020, 136
  • [46] Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors
    Risitano, Antonio
    Roth, Alexander
    Kulasekararaj, Austin
    Pu, Jeffrey
    Nishimura, Jun-Ichi
    Wright, Lilyan
    Appius, Anita
    Sostelly, Alexandre
    Sreckovic, Sasha
    Vignal, Charlotte
    Munir, Talha
    [J]. BLOOD, 2020, 136
  • [47] Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC).
    Kim, Dong-Wan
    Tan, Daniel Shao-Weng
    Aix, Santiago Ponce
    Sequist, Lecia V.
    Smit, Egbert F.
    Hida, Toyoaki
    Yang, James Chih-Hsin
    Felip, Enriqueta
    Seto, Takashi
    Grohe, Christian
    Wolf, Juergen
    Ko, Jinnie
    Diallo, Mariama
    Pultar, Philippe
    Giovannini, Monica
    Kim, Sang-We
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Befotertinib versus icotinib as first-line treatment in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer: A multicenter, randomized, open-label, controlled phase III study
    Lu, S.
    Zhou, J.
    Jian, H.
    Wu, L.
    Cheng, Y.
    Fan, Y.
    Fang, J.
    Chen, G.
    Zhang, Z.
    Lv, D.
    Jiang, L.
    Wu, R.
    Jin, X.
    Zhang, X.
    Zhang, J.
    Sun, G.
    Huang, D.
    Cui, J.
    Guo, R.
    Ding, L.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1038 - S1038
  • [49] Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer
    Eckardt, JR
    von Pawel, J
    Papai, Z
    Tomova, A
    Tzekova, V
    Crofts, TE
    Brannon, S
    Wissel, P
    Ross, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 2044 - 2051
  • [50] Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFRmutated non-small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study.
    Chen, Likun
    Hou, Xue
    Li, Meichen
    Wu, Guowu
    Feng, Weineng
    Su, Jin
    Jiang, Honghua
    Jiang, Guanming
    Zhang, Baishen
    Chen, Jing
    You, Zhixuan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345